- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07951268
Health and Economic After-effects in Leicester Tuberculosis Cohort (HEAL-TB)
Quantifying the Short to Long-term Physical, Psychological, and Socioeconomic Consequences of Pulmonary and Extra-pulmonary Tuberculosis in Patients in Leicester: a Longitudinal Cohort Study.
HEAL-TB (Health and Economic After-effects in Leicester Tuberculosis cohort) is a prospective observational study examining recovery among adults with pulmonary and extrapulmonary tuberculosis (TB). The study aims to understand how physical health, mental health, quality of life, daily activity, work and economic wellbeing change during TB treatment and up to 12 months after treatment completion.
Participants may join the study at different stages, from diagnosis until six months after completing TB treatment, and will be followed prospectively until 12 months after treatment completion. The study uses questionnaires, lung function testing, the Incremental Shuttle Walk Test, wrist-worn activity monitoring and information collected during routine clinical care. No experimental treatment is provided and participants continue to receive their usual NHS care.
The study aims to describe recovery over time, compare recovery following pulmonary and extrapulmonary TB, and identify factors associated with persistent health problems or poorer recovery.
Visão geral do estudo
Status
Condições
Descrição detalhada
HEAL-TB is a single-centre prospective observational cohort study designed to characterise physical, psychological and socioeconomic recovery among adults with pulmonary and extrapulmonary tuberculosis. Participants may enter the cohort at different stages of the tuberculosis pathway, from diagnosis or early treatment until six months after treatment completion, and complete the assessments applicable from their point of enrolment onwards. Follow-up continues until 12 months after treatment completion.
The study combines patient-reported outcome measures with objective assessments of physical function and routinely collected clinical information. Outcomes include health-related quality of life, mental health, work productivity and socioeconomic wellbeing, perceived recovery, lung function, functional exercise capacity, physical activity, sedentary behaviour and sleep. Relevant clinical records, imaging reports and routine investigation results are also reviewed to provide information on disease severity, treatment, complications and recovery.
The study is primarily descriptive and exploratory. Recovery trajectories will be characterised over time, with exploratory comparisons between pulmonary and extrapulmonary tuberculosis. Clinical and disease-related characteristics will also be explored as potential predictors of persistent impairment and poorer recovery. The study is intended to improve understanding of recovery beyond treatment completion and inform future approaches to follow-up, rehabilitation and supportive care for people affected by tuberculosis.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Jake Bodycot
- Número de telefone: +447551792221
- E-mail: jb1071@leicester.ac.uk
Locais de estudo
-
-
-
Leicester, Reino Unido, LE1 5WW
- University Hospitals of Leicester NHS Trust
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adults with pulmonary or extrapulmonary tuberculosis receiving care or follow-up through University Hospitals of Leicester NHS Trust. Participants may enter the cohort at different stages of the tuberculosis treatment and recovery pathway, from diagnosis until six months after treatment completion. Participants will be recruited through the UHL clinical tuberculosis service across Leicester Royal Infirmary, Glenfield Hospital and Leicester General Hospital and followed prospectively from enrolment until the applicable final assessment at 12 months after treatment completion.
Descrição
Inclusion Criteria:
- Aged 16 years or above.
- Any sex/gender.
- Pulmonary or extrapulmonary tuberculosis, receiving or having recently completed tuberculosis treatment, with tuberculosis care or follow-up provided through University Hospitals of Leicester NHS Trust. The latest entry point into the cohort is six months after treatment completion.
- Willing and able to provide informed consent to participate in the study.
Exclusion Criteria:
- Expected to move out of the area or unable to attend follow-up visits.
- Prisoners or people under custodial care.
- Currently involved in research or recently involved in other research.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Pulmonary Tuberculosis
Participants with pulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
|
Extrapulmonary Tuberculosis
Participants with extrapulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Health-related quality of life measured by EQ-5D-5L
Prazo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Health-related quality of life assessed using the EQ-5D-5L, including the EQ-5D-5L utility index and EQ Visual Analogue Scale (EQ VAS). Repeated measurements will be used to characterise changes in health-related quality of life during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Depressive symptoms measured by PHQ-9
Prazo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Anxiety symptoms measured by GAD-7
Prazo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Lung function measured by spirometry
Prazo: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Pre-bronchodilator spirometry including FEV1, FVC, FEV1/FVC ratio and percent predicted values. Repeated measurements will be used to characterise lung-function trajectories during recovery. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Physical activity measured by wrist-worn activity monitor
Prazo: Study entry and applicable follow-up assessments through 6 months after treatment completion
|
Wrist-worn activity monitoring over 7 days to measure daily physical activity, including steps per day and time spent sedentary and in different physical activity intensity levels. |
Study entry and applicable follow-up assessments through 6 months after treatment completion
|
|
Work productivity and activity impairment measured by WPAI
Prazo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Work Productivity and Activity Impairment questionnaire assessing work time missed, impairment while working, overall work impairment and activity impairment. Repeated measurements will characterise changes in work productivity and activity during treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Functional exercise capacity measured by Incremental Shuttle Walk Test
Prazo: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Functional exercise capacity assessed using the Incremental Shuttle Walk Test (ISWT), with total distance walked recorded in metres. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Respiratory-specific quality of life measured by St George's Respiratory Questionnaire
Prazo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Respiratory health status assessed using the St George's Respiratory Questionnaire in participants with pulmonary tuberculosis only, measuring respiratory symptoms, activity limitation and psychosocial impacts. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Participant-reported recovery from tuberculosis
Prazo: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Study-specific questions assessing whether participants consider themselves fully recovered from tuberculosis and how their perceived recovery has changed since the previous study visit. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Manish Pareek, University of Leicester
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1107
- 223512/Z/21/Z (Número de outro subsídio/financiamento: Wellcome Trust)
- 365242 (Outro identificador: IRAS)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
There is currently no plan to make individual participant-level data publicly available. Study findings will be disseminated in aggregate form.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .